|
M E M O R A N D U M
TO: David P. Spath, Ph.D., P.E., Chief
Division of Drinking Water and Environmental Management
Department of Health Services
601 North 7th Street, 2nd Floor
Sacramento, CA 94234-7320
FROM: George V. Alexeeff, Ph.D., DABT
Deputy Director for Scientific Affairs
DATE: June 2, 1999
SUBJECT: EXPEDITED EVALUATION OF RISK ASSESSMENT FOR TERTIARY BUTYL
ALCOHOL IN DRINKING WATER.
In response to your request of May 19, 1999, we have summarized
an interim assessment that the Office of Environmental Health Hazard
Assessment (OEHHA) staff made last year in connection with our assessment
of methyl tertiary butyl ether (MTBE) and based on limited data
available at that time. While this is still an interim assessment
with preliminary calculations, and by no means represents a full
risk assessment, it may be suitable for the purposes stated in your
request.
Tertiary butyl alcohol (TBA) has been used as a gasoline octane
booster and may be a food contaminant when used in coatings for
metallic items that contact food, or as a coating for paperboard
food containers. Human exposure can occur via skin contact, inhalation,
or ingestion. The Occupational Safety and Health Administration
has established a permissible exposure limit of 100 ppm or 300 mg/m3
for TBA. TBA is partially metabolized via demethylation in rats
to acetone and formaldehyde. TBA is a metabolite of MTBE and exposure
may occur through inhalation of MTBE fumes.
Compared to MTBE, relatively little toxicity data are available
for TBA. A bioassay was conducted by the National Toxicology Program
(NTP) in Fischer 344 rats and B6C3F1 mice exposed to TBA in drinking
water (NTP, 1994; Cirvello et al., 1995). Groups of 60 F-344 rats
were administered daily doses via drinking water of approximately
0, 85, 195, and 420 mg/kg-d in males and 0, 175, 330, and 650 mg/kg-d
in females. Ten animals in each group were sacrificed at 15 months
for evaluation; the remainder was exposed until the study was terminated
at 103 weeks. The high dose groups of both sexes experienced decreased
survival. Dose-related decrease in body weight gain was also observed.
All treated groups of females showed a dose-related increase in
kidney weight at the 15-month evaluation. Males exhibited increased
kidney weight at the mid and high doses. Nephropathy was seen in
all groups of treated females and caused early mortality in high
exposure groups. The study did not identify a NOAEL for chronic
TBA toxicity in the rat.
At the 24-month termination of the rat bioassay, the combined incidences
of adenomas and carcinoma of the renal tubules were found in 8/50,
13/50, 19/50, and 13/50 of the control, low, mid and high dose male
groups, respectively. The increased incidence in the mid dose group
was statistically significant (p = 0.01) by Fisher's exact test.
The increased mortality in the high dose group may have reduced
the observed incidence of renal tumors. The incidence of renal tubule
hyperplasia was elevated in all treatment groups. Although no renal
(or other) tumors were observed in female rats, the incidence of
renal hyperplasia was significantly elevated in the high dose group.
No renal tubule adenoma or carcinoma was observed in 227 control
male rats in the four studies comprising the recent NTP historical
control database for drinking water studies indicating the rarity
of these neoplasms in male rats. The pathogenesis of proliferative
lesions of renal tubule epithelium is thought to proceed from hyperplasia
to adenoma to carcinoma (Cirvello et al., 1995). The incidence of
renal tubule hyperplasia, adenoma and carcinoma was increased in
all treated male groups.
Groups of 60 B6C3F1 mice of each sex were administered TBA in drinking
water at doses of approximately 0, 535, 1035, and 2065 mg/kg-d in
males and 0, 510, 1015, and 2105 mg/kg-d in females. Reduced survival
was observed in the high dose groups. The incidence of thyroid follicular
cell hyperplasia was significantly elevated in all treatment groups
of males (5/60, 18/59, 15/59, 18/57) and in the mid and high dose
groups of females (19/58, 28/60, 33/59, 47/59). Follicular cell
adenomas were significantly higher in high dose females (9/59).
Chronic urinary bladder inflammation was seen in both sexes at the
high dose, but no urinary bladder neoplasias were observed. No NOAEL
was identified for chronic TBA toxicity in the mouse.
In conclusion, the increased incidence of renal tubule adenoma
or carcinoma, combined, in male rats and of thyroid gland follicular
cell adenoma in female mice is evidence of a carcinogenic response
to TBA.
TBA has been reported as negative in the Salmonella typhimurium
mutagenicity test, in a chromosome aberrations test in cultured
Chinese hamster ovary (CHO) cells, in a sister chromatid exchange
test in CHO cells, and in a mutation test in cultured mouse lymphoma
cells (Gold and Zeiger, 1997).
Due to the limited data available, the interim assessment for human
consumption will be based on the rat cancer bioassay noted above.
Since no mode of carcinogenic action has been established for TBA,
and following the U.S. EPA's 1996 Proposed Guidelines for Carcinogen
Risk Assessment (FR60: 17960-18011,4/23/96), a low dose linear dose-response
approach will be applied to the data for male rat kidney adenoma
and carcinoma. The analysis is summarized in Table 1.
Table 1. Dose Response Assessment of Tertiary Butyl Alcohol for
Rat Kidney Tumors
| Study |
Sex, Species |
Doses;
Tumor incidences |
Dose Response
X2, p, k |
LMSQ1*
(mg/kg-d)-1 |
ED10;
LED10
mg/kg-d |
CSF
(mg/
kg-d)-1 |
C,mg/L |
| NTP, 1994; Cirvello
et al., 1995 |
Male Fischer 344
Rat |
0, 85, 195,
420
mg/kg-d;
8/50,
13/50, 19/50(p<0.01), 13/50 |
5.12, 0.08, 3 |
3.3E-3 |
75.9;30.4 |
3.0 E-3 |
1.1E-2 |
Note: Dose response assessment performed with Tox_Risk v 3.5 and
body weight ¾ power scaling to human equivalent.
As can be seen in Table 1, the dose response fit was adequate exceeding
the Chi-square fit criterion of p ³ 0.05. The ED10 is the maximum
likelihood estimate of the dose giving a 10% tumor response and
the LED10 is the 95% lower bound on that dose. The carcinogen slope
factor (CSF) is simply the risk 0.1 divided by the LED10 or 3.3E-3
(mg/kg-d)-1. The drinking water interim assessment concentration
(C) is calculated as follows:
C = 70 kg x 10-6 = 0.0117 mg/L
3.0 x 10-3 (mg/kg-d)-1 x 2L/d
C = 0.012 mg/L (rounded) = 12 µg/L
Where: 10-6 is the negligible lifetime extra cancer risk criterion;
70 kg in the average human body weight;
3.3 x 10-3 (mg/kg-d)-1 is the human carcinogen slope factor (CSF);
2L/d is the average daily human total water consumption.
It should be noted that this calculation addresses exposures to
TBA via the oral route only. As noted above, other sources besides
water as well as other routes besides oral may be involved in human
exposures to TBA.
References:
NTP. (1994). Toxicology and Carcinogenesis Studies of t-Butyl Alcohol
(CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice. National Toxicology
Program, Technical Report No. 436, National Institutes of Health,
Public Health Service, U.S. Department of Health and Human Services,
Research Triangle Park, NC.
Cirvello JD, Radovsky A, Heath JE, Farnell DR, and Lindamood III
C. (1995). Toxicity and carcinogenicity of t-butyl alcohol in rats
and mice following chronic exposure in drinking water. Toxicol Indus
Health 11:151-165.
Gold LS and Zeiger, E eds. (1997). Handbook of Carcinogenic Potency
and Genotoxicity Databases. CRC Press, Boca Raton, FL.
If you need any additional information about this analysis, please
call me at (510) 622-3202.
|